Skip to main content
. 2021 Mar 15;10(3):29. doi: 10.1038/s41389-021-00317-y

Fig. 5. MSI2 knockdown increases the sensitivity of EGFR mutant xenograft tumors to erlotinib treatment.

Fig. 5

A Growth curve of subcutaneous xenografts PC9 cells stably expressing lentiviral vector as negative control (NC) or shRNA to MSI2 (sh1), and treated with vehicle or erlotinib (ERL) for 24 days. N = 5/group. B Quantification of tumors at endpoint of experiment in A. C Western blot analysis of MSI2, protein levels from treated tumors. D Quantification of western blot data from C; data normalized to β-actin. E Quantitative RT-PCR of mRNA collected from indicated xenograft tumors at the end of experiments. Negative controls are denoted NC. Data are normalized to 18S rRNA, as noted. Relative quantification (RQ) of gene expression was performed using 2−ΔΔCt method. Data are presented as normalized average RQ means in each group (n = 5) of animals. In all graphs, error bars represented by SEM. Statistical analysis was performed using unpaired two tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001 for all graphs.